Cochrane · systematic review · CD002786
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts
Mohamed, I, Kamarizan, MF, Da Silva, A · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
37
current version
GRADE rated
21
No studies
16
Included studies
NR
No studies 16 · 43.2%Ungraded 0 · 0%Very low 0 · 0%Low 10 · 27%Moderate 11 · 29.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aspirin compared to placebo in increasing patency of arteriovenous fistula or graft
Population: people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (28 days to 18 months) Aspirin vs placebo | OR 0.4 [0.07, 2.25] | 3 studies · 175 participants | Low Downgraded: inconsistency |
Duration of hospital stay Aspirin vs placebo | no estimate extracted | NR | No studies |
Complications (28 days to 18 months) Aspirin vs placebo | no estimate extracted | 3 studies · 175 participants | Low Downgraded: imprecision |
Number of related surgical or radiological interventions Aspirin vs placebo | no estimate extracted | NR | No studies |
Ticlopidine compared to placebo in increasing patency of arteriovenous fistula or graft
Population: people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fistulae thromboses (up to 1 month) Ticlopidine vs placebo | OR 0.45 [0.25, 0.82] | 3 studies · 339 participants | Moderate Downgraded: risk of bias |
Duration of hospital stay Ticlopidine vs placebo | no estimate extracted | NR | No studies |
Complications (up to 1 month) Ticlopidine vs placebo | no estimate extracted | 3 studies · 339 participants | Low Downgraded: risk of bias, inconsistency |
Number of related surgical or radiological interventions Ticlopidine vs placebo | no estimate extracted | NR | No studies |
Dipyridamole compared to placebo for increasing patency of arteriovenous graft
Population: people with ESRD receiving haemodialysis through an arteriovenous graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (up to 18 months) Dipyridamole vs placebo | OR 0.46 [0.11, 1.94] | 1 study · 42 participants | Moderate Downgraded: imprecision |
Duration of hospital stay Dipyridamole vs placebo | no estimate extracted | NR | No studies |
Complications (up to 18 months) Dipyridamole vs placebo | no estimate extracted | 1 study · 42 participants | Low Downgraded: imprecision |
Number of related surgical or radiological interventions Dipyridamole vs placebo | no estimate extracted | NR | No studies |
Dipyridamole plus aspirin compared to placebo for improving patency of arteriovenous graft
Population: people with ESRD receiving haemodialysis through an arteriovenous graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (up to 18 months) Dipyridamole plus aspirin vs placebo | OR 0.64 [0.16, 2.56] | 1 study · 41 participants | Moderate Downgraded: imprecision |
Duration of hospital stay Dipyridamole plus aspirin vs placebo | no estimate extracted | NR | No studies |
Complications (up to 18 months) Dipyridamole plus aspirin vs placebo | no estimate extracted | 1 study · 41 participants | Low Downgraded: imprecision |
Number of related surgical or radiological interventions Dipyridamole plus aspirin vs placebo | no estimate extracted | NR | No studies |
Warfarin compared to placebo for improving patency of arteriovenous graft
Population: people with ESRD receiving haemodialysis through an arteriovenous graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (up to 37 months) Warfarin vs placebo | OR 1.76 [0.78, 3.99] | 1 study · 107 participants | Low Downgraded: imprecision |
Duration of hospital stay Warfarin vs placebo | no estimate extracted | NR | No studies |
Complications (up to 37 months) Warfarin vs placebo | no estimate extracted | 1 study · 107 participants | Low |
Number of related surgical or radiological interventions Warfarin vs placebo | no estimate extracted | NR | No studies |
Fish oil compared to placebo for improving patency of arteriovenous graft
Population: people with ESRD receiving haemodialysis through an arteriovenous graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (up to 12 months) Fish oil vs placebo | OR 0.24 [0.03, 1.95] | 2 studies · 220 participants | Low Downgraded: imprecision, inconsistency |
Duration of hospital stay Fish oil vs placebo | no estimate extracted | NR | No studies |
Complications (up to 12 months) Fish oil vs placebo | no estimate extracted | 1 study · 196 participants | Moderate Downgraded: imprecision |
Radiological or surgical intervention (up to 12 months) Fish oil vs placebo | OR 0.64 [0.36, 1.12] | 1 study · 196 participants | Moderate Downgraded: imprecision |
Clopidogrel compared to placebo for increasing patency of arteriovenous fistula
Population: people with ESRD receiving haemodialysis through an arteriovenous fistula
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fistula thrombosis (42 days to 6 months) Clopidogrel vs placebo | OR 0.4 [0.13, 1.19] | 2 studies · 959 participants | Moderate Downgraded: imprecision |
Duration of hospital stay Clopidogrel vs placebo | no estimate extracted | NR | No studies |
Complication: all bleeding (up to 6 months) Clopidogrel vs placebo | OR 1.06 [0.55, 2.03] | 2 studies · 970 participants | Moderate Downgraded: imprecision |
Complication: mortality (up to 6 months) Clopidogrel vs placebo | OR 1 | 2 studies · 970 participants | Moderate Downgraded: imprecision |
Number of related surgical or radiological interventions (42 days) Clopidogrel vs placebo | OR 0.69 [0.26, 1.82] | 1 study · 866 participants | Moderate Downgraded: imprecision |
Sulphinpyrazone compared to placebo for increasing patency of arteriovenous fistula or graft
Population: people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Graft thrombosis (up to 3 months) Sulphinpyrazone vs placebo | OR 0.43 [0.03, 5.98] | 1 study · 16 participants | Low Downgraded: imprecision |
Duration of hospital stay Sulphinpyrazone vs placebo | no estimate extracted | NR | No studies |
Complications (up to 3 months) Sulphinpyrazone vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Number of related surgical or radiological interventions Sulphinpyrazone vs placebo | no estimate extracted | NR | No studies |
Glyceryl trinitrate patch compared to placebo for increasing patency of arteriovenous fistula
Population: people with ESRD receiving haemodialysis through an arteriovenous fistula
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fistula failure (6 weeks) Glyceryl trinitrate patch vs placebo | OR 1.26 [0.63, 2.54] | 1 study · 167 participants | Moderate Downgraded: imprecision |
Duration of hospital stay Glyceryl trinitrate patch vs placebo | no estimate extracted | NR | No studies |
Complications (6 weeks) Glyceryl trinitrate patch vs placebo | no estimate extracted | 1 study · 167 participants | Moderate Downgraded: imprecision |
Number of related surgical or radiological interventions Glyceryl trinitrate patch vs placebo | no estimate extracted | NR | No studies |